4.1.8 Estimated life expectancy of at least 12 weeks. 
4.1.9 Patients must be anti-HIV cintibody negative. 
4.1.10 Investigator must have obtained signed informed consent from patient. 
4.1.11 If patient is female, she must eitiier not be of child-bearing potential by reason of 
surgery, radiation or menopause or, if of child-bearing potential, using an 
approved method of contraception. 
4.1.12 Patients must be immunocompetent by having at least 2/7 positive skin tests on 
the Merieux Multitest and by having a PHA lymphocyte response in the normal 
rainge. 
4.2 Exclusion Criteria 
4.2.1 Patients with an active autoimmune disease. 
4.2.2 Patients with active hepatitis B (chronic or acute) or HBs Ag positive, and 
patients who are HIV sero-positive. 
4.2.3 Patients with any active infection requiring parenteral antibiotics. 
4.2.4 Radiation, chemotherapy, steroidal therapy within the past three weeks. 
Surgery within the past 2 weeks. 
4.2.5 Patients receiving concurrent anticancer drug therapy, any immunosuppressive 
drugs and any other experimental therapy. 
4.2.5 Immunoincompetence as defined above in 4.1.12. 
4.2.7 Patients with diabetes mellitus who are not controlled by medical treatment. 
4.2.8 Patients with significant psychiatric disorders that would make compliance to 
the Protocol difficult or would compromise ability to give informed consent 
5.0 STUDY DRUG 
The study drug (VCL-1005) wiU be supplied as three sterile vials containing (i) HLA-B7 
plasmid DNA, (ii) DMRIE/DOPE Upid mixture and (iU) lactated Ringer’s. All 
components will be stable for at least eight weeks under recommended storage 
Recombinant DNA Research, Volume 19 
[245] 
